Evidence map›Paper›PMID 32338643›Full record

ArticleThe Journal of clinical investigation2020

Human Plasmodium vivax mosquito experimental transmission.

David J Sullivan, Peter Agre

Open access · bronzeAbstract readComment
In one paragraph

Article in The Journal of clinical investigation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

David J Sullivan
Peter Agre
Johns Hopkins University · US

Funding

Optimized Combination Antimalarial Drug TherapyR01AI111962 · NIAID · GEORGETOWN UNIVERSITY · PI ROEPE, PAUL D., SULLIVAN, DAVID JOSEPH · 2014 to 2018
$4.9M
Quantum model repurposing of cethromycin for liver stage malariaR21TR001737 · NCATS · JOHNS HOPKINS UNIVERSITY · PI SULLIVAN, DAVID JOSEPH · 2016 to 2017
$612k
NCATS NIH HHS R21 TR001737NIAID NIH HHS R01 AI111962
6 · The paper itself

Abstract

Plasmodium vivax bench research greatly lags behind Plasmodium falciparum because of an inability to culture in vitro. A century ago, intentionally inducing a malaria infection was a strategy commonly used to cure late-stage syphilis. These controlled human malaria infections were used with expertise and persisted to the end of World War II. While controlled malaria liver-stage infection has been achieved for both P. vivax and P. falciparum, controlled human transmission to mosquitoes falls short for both species. In this issue of the JCI, Collins et al. present groundbreaking work that establishes a system to transmit P. vivax gametocytes from humans to mosquitoes. The authors injected a unique human isolate of P. vivax that reached high gametocyte density within weeks. This study provides a technical advance that will facilitate the study and eradication of the human parasite P. vivax.

Indexed as

CulicidaeMalaria, FalciparumMalaria, VivaxAnimalsHumansPlasmodium falciparumPlasmodium vivax

Identifiers

PMID32338643
PMCPMC7259994
OpenAlexW3018699361

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.